The Beatrice Hunter Cancer Research Institute logo
  • CRTP Integrated Learning Sessions

    Thursday, January 21, 2021

    • Time: 10:00 am - 12:00 pm
    • Location: Videoconference
    • Presenter: Ms. Heather Hogan and Dr. Jeanette Boudreau
    • Topic: Immunotherapy

    The Beatrice Hunter Cancer Research Institute CRTP Integrated Learning Session (ILS) will be held on Thursday 21 January from 10:00am-12:00pm AST via videoconference  

    Integrated Learning Sessions consist of presentations from various cancer research perspectives to better understand and address a topic. 

    ILS sessions are mandatory for CRTP Trainees – please contact if you are unable to attend. Trainees recognize the benefit of having supervisors in attendance at these sessions and we hope that all supervisors of CRTP trainees will attend as many sessions as possible.

    Topic: Immunotherapy


    Living Beyond Lung Cancer

    Presented by:

    Ms. Heather Hogan
    Patient Partner and Lung Cancer Advocate

    Heather Hogan (BA, Bed, Med) is a retired teacher and school administrator from Woodstock, New Brunswick.  Having been diagnosed with Stage 3a Adenocarcinoma lung cancer in 2012 (with a 15% chance of surviving five years), Heather knows first hand the importance of research. Heather is currently a Patient Partner with the Maritime SPOR Support Unit’s Scientific Leadership Committee and a Peer Support member with Lung Cancer Canada as part of their Programs Committee.“I believe in the advancement of all cancer research as well as promoting patient engagement in research.  I have seen the benefits of collaboration between stakeholders and I have also learned that research done in Atlantic Canada can compete both nationally and internationally.”


    Human Natural Killer Cell Immunogenetics: Function and Application for Precise Immunotherapy 

    Learning objectives: 
    1. Understand the basics of cellular therapy, broadly, and specifically with respect to NK cells.
    2. Understand the roles of “missing self” and “missing ligand” reactivity and its relationship to NK immunogenetics, BMT and cancer therapy.
    3. Describe the potential role(s) of NK cells in cancer surveillance and treatment.

    Presented by:

    Dr. Jeanette Boudreau, PhD
    Assistant Professor and Cameron Cancer Scientist Head, Human Natural Killer cell laboratory Departments of Microbiology and Immunology and Pathology, Dalhousie University

    The Boudreau laboratory studies human natural killer cell biology, and the roles of human NK cells in disease and immunotherapy. Using human NK cell immunogenetics for guidance, we aim to understand how diversity in NK cell subsets is conferred and maintained, and can be leveraged to effect maximal NK cell-mediated control of disease. We work with primary human samples, humanized mouse models, and high parameter microscopy and flow cytometry to unravel the roles of NK cell receptor expression and co-expression in determining NK cell function. In this integrated learning session, we will discuss how human NK immunogenetics predict NK cell function and the history and future use of these elements in precision therapy for cancer. 


    PLEASE NOTE: When joining a meeting, please ensure that your microphone and camera are enabled. Using Chrome or Microsoft Edge is recommended. It is important to mute mics when not in use so that background noise is minimal. For technical support please contact MedIT: CRichardson@Dal.Ca


    The videoconference connection information will be sent to CRTP trainees and supervisors in advance via email. For all other members, if you are interested in joining this session, please contact 48 hours in advance for connection information.


Site by: Spectacle Group